Analysed ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) News Sources
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
31-03-2026
yahoo.com
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
03-02-2026
yahoo.com
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
27-01-2026
yahoo.com
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
06-01-2026
yahoo.com
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
08-12-2025
yahoo.com
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
03-12-2025
yahoo.com
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
02-12-2025
yahoo.com
What is the current price of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)?
The current price of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) is $0.197.
ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) since the previous trading day is $0.0063.
ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) since the previous trading day is 3.3036%.
What is the most recent average sentiment score for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)?
The most recent average sentiment score for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)?
The most recent sentiment for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) is .
SEC-8K** Filing Available For ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.